Eli Lilly Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Eli Lilly Bundle
Actionable Strategy Starts Here
Curious about Eli Lilly's product portfolio performance? Our preview of their BCG Matrix offers a glimpse into how their offerings stack up as Stars, Cash Cows, Dogs, or Question Marks. Understand the strategic implications of these placements and unlock actionable insights.
Don't stop at a glimpse; the full Eli Lilly BCG Matrix report provides a comprehensive breakdown of each product's market share and growth rate. Equip yourself with the detailed analysis and strategic recommendations needed to optimize Eli Lilly's product pipeline and investment decisions.
Gain a competitive edge by purchasing the complete Eli Lilly BCG Matrix. This detailed report is your key to understanding their market position, identifying growth opportunities, and making informed strategic choices for future success.
Stars
Mounjaro (Tirzepatide)
Mounjaro, also known by its active ingredient tirzepatide, is a significant growth engine for Eli Lilly, holding a strong position in the booming GLP-1 agonist market. This drug, initially approved for type 2 diabetes, has shown remarkable financial performance, with Q1 2025 revenue reaching an impressive $3.84 billion, a substantial 111% increase compared to the previous year.
The trajectory for Mounjaro is exceptionally strong, with projections indicating it could become the global best-selling drug by 2030. Analysts anticipate its annual sales to hit an astounding $36 billion, a testament to its current market dominance and its considerable future growth potential.
Zepbound (Tirzepatide)
Zepbound, Eli Lilly's groundbreaking obesity treatment, firmly establishes itself as a Star in the BCG Matrix. Its position is driven by the explosive growth of the weight-loss market and Zepbound's commanding presence within it.
Launched in late 2023, Zepbound demonstrated remarkable financial performance, achieving $2.31 billion in revenue in Q1 2025. This figure represents a substantial 345% surge compared to the same period in 2024, underscoring its rapid market penetration and high demand.
In 2025, Zepbound captured an impressive 53% share of the U.S. obesity drug market. Analysts project its continued success, forecasting it to become the third-highest selling drug worldwide by 2030, solidifying its status as a key growth driver for Eli Lilly.
Verzenio
Verzenio, Eli Lilly's groundbreaking oncology drug for breast cancer, demonstrates a robust market position and sustained growth. Its Q1 2025 worldwide revenue reached $1.16 billion, a 10% increase from the previous quarter. This follows a significant 36% surge in Q4 2024, where it generated $1.56 billion.
The drug's expansion into adjuvant therapy for early-stage breast cancer is a critical factor in its ongoing success. This strategic positioning solidifies Verzenio as a primary contributor to Eli Lilly's long-term revenue stream, reflecting its strong performance within the BCG Matrix as a potential star or cash cow.
Kisunla (Donanemab)
Kisunla, or donanemab, is positioned as a Star in Eli Lilly's BCG Matrix. Its recent U.S. approval in July 2024 and a positive EMA opinion in July 2025 for early Alzheimer's disease highlight its significant potential in a market with vast unmet medical needs. This therapy targets the underlying pathology of Alzheimer's, signaling a new era in treatment and market capture.
The market for Alzheimer's treatments is substantial, with estimates suggesting it could reach tens of billions of dollars annually in the coming years. Kisunla's ability to address the disease's progression places it at the forefront of this growing sector. Eli Lilly's investment in neuroscience research, including donanemab, underscores their commitment to high-growth, high-impact therapeutic areas.
- Market Potential: The global Alzheimer's disease market was valued at approximately $5.9 billion in 2023 and is projected to grow significantly, driven by an aging population and advancements in treatment.
- Clinical Efficacy: Donanemab has demonstrated a notable reduction in cognitive and functional decline in clinical trials, a key factor in its Star classification.
- Regulatory Milestones: U.S. FDA approval in July 2024 and a positive CHMP opinion from the EMA in July 2025 solidify its market entry and future growth trajectory.
- Competitive Landscape: While other treatments exist, Kisunla's unique mechanism of action and demonstrated efficacy position it strongly against competitors.
Omvoh
Omvoh, a significant player in Eli Lilly's expanding portfolio, is categorized as a Star within the BCG matrix. This classification stems from its recent market introduction for inflammatory bowel disease (IBD) and its projected substantial impact on Eli Lilly's future revenue streams.
Launched in 2022, Omvoh is anticipated to be a key revenue generator for Eli Lilly in 2025, aligning with the company's strategic focus on high-growth segments like immunology. This positions it as a strong contender for continued investment and market share expansion.
- Omvoh's Market Position: Classified as a Star due to its recent launch and strong growth potential in the IBD market.
- Revenue Contribution: Expected to be a significant driver of Eli Lilly's revenue in 2025, reflecting its status as a 'New Product'.
- Strategic Alignment: Represents Eli Lilly's strategic expansion into the lucrative immunology therapeutic area.
- Growth Outlook: Its trajectory suggests continued investment and market penetration, solidifying its Star status.
High-Growth Drugs Propel Revenue for the Company!
Eli Lilly's Stars represent products with high market share in high-growth industries, demanding significant investment to maintain their position. Mounjaro and Zepbound, for instance, are leading the booming GLP-1 and obesity markets, respectively, with exceptional revenue growth in early 2025. Kisunla, recently approved for Alzheimer's, is poised to capture a substantial share of a market with immense unmet need. Omvoh, a newer immunology drug, is also showing strong potential in the inflammatory bowel disease sector.
| Product | Therapeutic Area | Q1 2025 Revenue (Billions USD) | Year-over-Year Growth | Market Position |
|---|---|---|---|---|
| Mounjaro | Type 2 Diabetes / Obesity | 3.84 | 111% | Star |
| Zepbound | Obesity | 2.31 | 345% | Star |
| Verzenio | Oncology | 1.16 (Q1 2025) / 1.56 (Q4 2024) | 10% (QoQ) / 36% (YoY Q4) | Star/Cash Cow |
| Kisunla (donanemab) | Alzheimer's Disease | N/A (Launched July 2024) | N/A | Star |
| Omvoh | Inflammatory Bowel Disease | N/A (Launched 2022) | Projected High Growth | Star |
What is included in the product
Detailed Word Document
The Eli Lilly BCG Matrix provides a strategic overview of its product portfolio, categorizing them as Stars, Cash Cows, Question Marks, or Dogs to guide investment decisions.
Customizable Excel Spreadsheet
The Eli Lilly BCG Matrix offers a clear, visual pain point reliever by instantly categorizing products, simplifying strategic decisions.
Cash Cows
Jardiance
Jardiance, a key SGLT2 inhibitor, is a strong cash cow for Eli Lilly, contributing significantly to its portfolio. It's approved for type 2 diabetes, heart failure, and kidney disease, showcasing its broad therapeutic reach.
In Q1 2025, Jardiance generated $687 million in revenue, marking a solid 19% increase year-over-year. This steady growth reflects its mature market position, a hallmark of a cash cow product.
The drug maintains a dominant market share within the U.S. SGLT2 inhibitor market. Through its partnership with Boehringer Ingelheim, Jardiance consistently delivers substantial and reliable cash flow to Eli Lilly.
Taltz
Taltz, a key immunology product from Eli Lilly, fits the cash cow profile within the BCG matrix due to its strong market position and dependable revenue streams. Its consistent performance in treating conditions like psoriasis fuels stable cash flow for the company.
In the fourth quarter of 2024, Taltz achieved worldwide revenue of $952 million, marking a significant 21% increase. For the first half of 2024, sales amounted to $1.43 billion, underscoring its robust and growing market presence.
This reliable financial contribution from Taltz allows Eli Lilly to allocate resources towards other promising, high-growth segments of its product portfolio, demonstrating its strategic value as a mature, high-earning asset.
Olumiant
Olumiant, a key product for Eli Lilly, is a prime example of a cash cow within the company's portfolio. Its effectiveness in treating conditions like rheumatoid arthritis and alopecia areata has driven significant revenue.
In 2024, Olumiant achieved global sales approaching $1 billion, underscoring its status as a reliable income generator. This consistent financial contribution is vital for Eli Lilly's ongoing research and development efforts in new therapeutic areas.
Humalog
Humalog, a cornerstone insulin product for Eli Lilly, exemplifies a cash cow within the BCG matrix. Its mature market status and established patient base contribute to consistent, reliable revenue streams. Despite being an older product, its widespread use underpins its role as a significant cash generator.
In Q4 2024, Humalog demonstrated robust financial performance, with worldwide revenue reaching $619.9 million. This notable increase was primarily driven by a one-time pricing adjustment, rather than an expansion in sales volume. Nevertheless, this figure underscores Humalog's continued importance and its ability to generate substantial income for Eli Lilly.
- Humalog's Q4 2024 worldwide revenue: $619.9 million
- Revenue driver: One-time pricing adjustment
- Market position: Mature, stable revenue generation
- Portfolio role: Foundational product with consistent cash flow
Cyramza
Cyramza, an oncology treatment, operates as a cash cow for Eli Lilly, consistently generating revenue in a well-established market. Its performance in the first half of 2024 saw sales of $478 million, demonstrating its stable income-generating capability.
As a product launched before 2022 and classified as a 'Growth Product', Cyramza continues to provide reliable earnings without the need for substantial new investment to capture further market share. This mature product status allows it to be a significant contributor to Eli Lilly's overall financial health.
- Product: Cyramza (Oncology)
- BCG Matrix Classification: Cash Cow
- H1 2024 Sales: $478 million
- Market Position: Mature, stable revenue generator
Cash Cows: The Financial Backbone
Eli Lilly's established products like Jardiance, Taltz, and Olumiant are strong cash cows, generating consistent revenue that fuels the company's growth initiatives. These mature products benefit from significant market share and broad therapeutic approvals, ensuring reliable financial contributions.
Humalog, an insulin product, also functions as a cash cow, providing stable income despite its mature market status. Cyramza, an oncology treatment, similarly contributes dependable earnings, reinforcing the company's robust financial foundation.
| Product | BCG Classification | H1 2024 Revenue | Q4 2024 Revenue | Key Therapeutic Area |
|---|---|---|---|---|
| Jardiance | Cash Cow | N/A | $687 million (Q1 2025) | Diabetes, Heart Failure, Kidney Disease |
| Taltz | Cash Cow | $1.43 billion (H1 2024) | $952 million | Immunology (Psoriasis) |
| Olumiant | Cash Cow | N/A | Approaching $1 billion (2024) | Rheumatoid Arthritis, Alopecia Areata |
| Humalog | Cash Cow | N/A | $619.9 million | Diabetes (Insulin) |
| Cyramza | Cash Cow | $478 million | N/A | Oncology |
What You See Is What You Get
Eli Lilly BCG Matrix
The Eli Lilly BCG Matrix you are previewing is the identical, fully formatted document you will receive immediately after purchase. This means no watermarks, no placeholder text, and no altered content – just the complete, analysis-ready strategic tool for evaluating Eli Lilly's product portfolio.
Dogs
Trulicity
Trulicity, a once-leading diabetes medication, is now considered a Dog in Eli Lilly's portfolio. Its market position has eroded significantly, with Q1 2025 sales dropping 25% to $1.25 billion.
This decline stems from fierce competition, particularly from newer GLP-1 agonists such as Mounjaro and Wegovy, which are capturing market share and customer preference.
Despite its past success, Trulicity faces ongoing challenges from price pressure and evolving market trends, dimming its future growth potential.
Humulin
Humulin, an established insulin product from Eli Lilly, is categorized as a Dog in the BCG Matrix. This classification stems from its low growth potential and diminishing market share within the intensely competitive insulin sector.
In the first half of 2024, Humulin generated sales of $430 million, a figure that underscores its status as a mature product facing considerable market challenges. Eli Lilly's strategic priorities are increasingly directed towards developing and marketing novel, innovative diabetes therapies.
Basaglar
Basaglar, an established insulin product, currently occupies the Dog quadrant of Eli Lilly's BCG Matrix. This classification stems from its position in a low-growth market segment with a declining market share.
In the first half of 2024, Basaglar generated sales of $338 million. However, this performance is overshadowed by intense competition and significant pricing pressures within the mature insulin market.
Eli Lilly is likely redirecting investment and resources away from products like Basaglar, prioritizing its more promising pipeline assets that offer higher future growth potential.
Forteo
Forteo, a medication focused on bone health, fits into the Dog category within Eli Lilly's BCG Matrix. This classification stems from its low market growth potential and a likely shrinking market share. The drug's 2023 sales reached $533 million, but there are no recent indications of growth that would suggest a comeback.
As an established product, Forteo contributes minimal new revenue to Eli Lilly. It is not a priority for future investment when contrasted with the company's more innovative and promising drug pipeline.
- Product: Forteo
- Therapeutic Area: Bone Health
- BCG Matrix Classification: Dog
- 2023 Sales: $533 million
Zyprexa
Zyprexa, a long-standing neuroscience product, is categorized as a Dog in Eli Lilly's BCG Matrix. This classification stems from its presence in a mature market offering limited prospects for significant expansion. Its market share is also likely stagnant, reflecting its mature life cycle stage.
While Zyprexa generated substantial revenue, with 2023 sales reaching $1.695 billion, its growth trajectory is minimal. Without new developments or market drivers, the product is essentially a break-even or low-surplus cash generator for the company. Eli Lilly's strategic emphasis has clearly moved towards its newer neuroscience treatments.
- Product: Zyprexa (Eli Lilly)
- BCG Matrix Category: Dog
- Market Characteristics: Mature, low growth potential
- 2023 Sales: $1.695 billion
- Strategic Implication: Focus has shifted to newer neuroscience products.
The Pharmaceutical Giant's "Dogs": Declining Assets
Eli Lilly's portfolio includes several products classified as Dogs in the BCG Matrix, indicating they operate in low-growth markets with declining market share. These products, while potentially still generating some revenue, are not strategic priorities for future investment. The company is likely focusing resources on its more promising pipeline assets and newer, high-growth products.
Products like Trulicity, Humulin, Basaglar, Forteo, and Zyprexa exemplify this Dog category. Trulicity's sales dropped 25% to $1.25 billion in Q1 2025 due to competition. Humulin and Basaglar, mature insulin products, saw first-half 2024 sales of $430 million and $338 million respectively, facing intense market pressure. Forteo, a bone health medication, had $533 million in 2023 sales with no growth, while Zyprexa, a neuroscience drug, generated $1.695 billion in 2023 but has minimal growth prospects.
| Product | Therapeutic Area | BCG Classification | 2023/H1 2024 Sales Data | Market Dynamics |
|---|---|---|---|---|
| Trulicity | Diabetes | Dog | Q1 2025: $1.25 billion (-25%) | High competition, declining market share |
| Humulin | Diabetes (Insulin) | Dog | H1 2024: $430 million | Mature market, intense competition |
| Basaglar | Diabetes (Insulin) | Dog | H1 2024: $338 million | Low growth, significant pricing pressure |
| Forteo | Bone Health | Dog | 2023: $533 million | Low growth potential, shrinking market share |
| Zyprexa | Neuroscience | Dog | 2023: $1.695 billion | Mature market, minimal growth prospects |
Question Marks
Orforglipron
Orforglipron, Eli Lilly's promising oral GLP-1 agonist, fits squarely into the Question Mark category of the BCG matrix. It possesses immense growth potential in the burgeoning obesity and type 2 diabetes markets, yet currently holds zero market share as it awaits regulatory approval.
Positive Phase 3 trial results for Orforglipron in treating type 2 diabetes and obesity highlight its significant disruptive potential. The convenience of an oral pill form could revolutionize treatment accessibility, contrasting with existing injectable therapies.
Eli Lilly anticipates regulatory submissions for Orforglipron by the close of 2025. Analysts project that if approved, the drug could achieve annual sales of $10 billion by 2030, underscoring its high-growth, high-uncertainty status.
Retatrutide
Retatrutide, Eli Lilly's promising triple G-agonist, is positioned as a significant Question Mark within the company's BCG matrix for the cardiometabolic sector. Currently in Phase 3 trials, it holds the potential to revolutionize weight management with superior efficacy compared to current GLP-1 therapies.
Eli Lilly is channeling substantial resources into Retatrutide's development, reflecting its belief in its future market dominance. This investment aims to capture a substantial share of the growing obesity and diabetes markets, projected to reach hundreds of billions of dollars globally by the end of the decade.
Imlunestrant
Imlunestrant, a promising late-stage oncology asset targeting metastatic breast cancer, is positioned as a Question Mark in Eli Lilly's BCG Matrix. Its high growth potential is contingent on a successful launch, anticipated in 2025.
This novel therapy is expected to be a significant contributor to Eli Lilly's future revenue streams, underscoring the company's strategic focus on advancing its oncology portfolio with cutting-edge treatments. The drug's market penetration and subsequent success will be critical for its transition from a Question Mark to a Star.
Lebrikizumab
Lebrikizumab, an investigational biologic for inflammatory conditions, is positioned as a Question Mark for Eli Lilly. This large molecule is currently in Phase 3 trials for conditions like chronic rhinosinusitis with nasal polyps (CRSwNP) and allergic rhinitis, areas with substantial unmet patient needs.
Its potential success in these indications could significantly bolster Eli Lilly's immunology portfolio, opening up new revenue streams. For instance, the global market for biologics in inflammatory diseases is substantial, with projections indicating continued growth through 2030.
- Lebrikizumab's status: Phase 3 development for CRSwNP and allergic rhinitis.
- Market potential: Addresses significant unmet needs in inflammatory conditions.
- Strategic importance: Could expand Eli Lilly's immunology market share.
Remternetug
Remternetug represents a significant Question Mark within Eli Lilly's portfolio, highlighting their deep commitment to Alzheimer's disease research beyond their well-known candidate, donanemab.
This drug is currently in Phase 3 trials, indicating a substantial investment and high hopes for its potential in a market desperately seeking effective treatments. The Alzheimer's market is projected to grow substantially, with estimates suggesting it could reach over $100 billion globally by 2028, underscoring the high growth prospects for successful therapies.
The ultimate success of Remternetug hinges on its clinical trial results and the subsequent regulatory approvals it receives from bodies like the FDA. Eli Lilly has invested heavily in its neuroscience pipeline, with Remternetug being a key component of this strategy.
- Drug Candidate: Remternetug
- Development Stage: Phase 3
- Therapeutic Area: Alzheimer's Disease
- Market Potential: High growth in a large unmet need market
High-Growth, High-Risk: The Company's "Question Marks"
Eli Lilly's pipeline is rich with potential "Question Marks" – products in high-growth markets with uncertain futures. Orforglipron, an oral GLP-1 agonist, exemplifies this, targeting the massive obesity and type 2 diabetes markets. Retatrutide, a triple G-agonist, also falls into this category, aiming for superior efficacy in weight management.
Lebrikizumab, for inflammatory conditions, and Imlunestrant, an oncology asset, represent further Question Marks, each with significant market potential contingent on successful development and launch. Remternetug, in Alzheimer's research, is another key Question Mark, reflecting the company's substantial investment in a high-need area.
These products, while not yet market leaders, are poised for substantial growth if clinical trials and regulatory hurdles are cleared. Eli Lilly's strategic focus on these high-potential, high-risk assets underscores their commitment to innovation and future market leadership.
| Product | Therapeutic Area | Development Stage | Market Potential | BCG Category |
| Orforglipron | Obesity, Type 2 Diabetes | Phase 3 | High (>$10B by 2030 est.) | Question Mark |
| Retatrutide | Weight Management, Diabetes | Phase 3 | High (hundreds of billions globally) | Question Mark |
| Imlunestrant | Metastatic Breast Cancer | Late-stage (launch 2025 est.) | Significant future revenue | Question Mark |
| Lebrikizumab | Inflammatory Conditions (CRSwNP, Allergic Rhinitis) | Phase 3 | Substantial (growing biologics market) | Question Mark |
| Remternetug | Alzheimer's Disease | Phase 3 | High (>$100B by 2028 est.) | Question Mark |
BCG Matrix Data Sources
Our BCG Matrix leverages comprehensive market data, including financial reports, industry analysis, and sales figures, to accurately position products.
